C. Bentzen

发表

Direct Determinationof LipoproteinCholesterolDistributionwith Micro-ScaleAffinityChromatogrnphyColumns

C. Bentzen, K. Acuff, B. Marechal, 2004 .

The Bile Acid Nuclear Receptor FXR and the Bile Acid Binding Protein IBABP Are Differently Expressed in Colon Cancer

A. de Gottardi, J. Dufour, C. Maurer, 2004, Digestive Diseases and Sciences.

Direct determination of lipoprotein cholesterol distribution with micro-scale affinity chromatography columns.

C. Bentzen, K. Acuff, B. Marechal, 1982, Clinical chemistry.

Role of the intestinal acyl-CoA:cholesterol acyltransferase activity in the hyperresponse of diabetic rats to dietary cholesterol.

C. Wollheim, E. Niesor, P. Maechler, 1992, Journal of lipid research.

The nuclear oxysterol receptor LXRα is expressed in the normal human breast and in breast cancer

D. Vigushin, S. Ali, Y. Dong, 2004, Medical oncology.

Apomine, a Novel Hypocholesterolemic Agent, Accelerates Degradation of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase and Stimulates Low Density Lipoprotein Receptor Activity*

C. Ammon-Zufferey, D. Masson, E. Niesor, 2004, Journal of Biological Chemistry.

The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol.

E. Niesor, J. Flach, P. Villemin, 2000, Biochemical and biophysical research communications.

SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis.

K. Suckling, P. Groot, E. Niesor, 1997, Atherosclerosis.

The Novel Cholesterol-lowering Drug SR-12813 Inhibits Cholesterol Synthesis via an Increased Degradation of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase*

K. Suckling, D. Patel, E. Niesor, 1996, The Journal of Biological Chemistry.

Hypocholesterolaemic and Antiatherosclerotic Effects of Tetra-iso-propyl 2-(3,5-Di-tert-butyl-4-hydroxyphenyl)ethyl-1, 1-diphosphonate (SR-9223i)

K. Suckling, E. Niesor, W. Kerns, 2000, Arzneimittelforschung.

The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases.

E. Niesor, A. Pérez, J. Flach, 2001, Current pharmaceutical design.

Synthesis of [24, 25-3H]cholesterol: a new substrate for determining the rate of cholesterol side chain oxidation.

K. Brendel, C. Bentzen, 1979, Journal of lipid research.

Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.

Peter L Bonate, P. Bonate, Simon Floret, 2004, British journal of clinical pharmacology.

gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity.

E. Niesor, C. Bentzen, L. Nguyen, 1987, Journal of medicinal chemistry.

Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug.

D. Alberts, S. Salmon, D. Garcia, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression of Nuclear Receptors and Apo E Secretion During the Differentiation of Monocytic THP-1 cells into Macrophages

E. Niesor, A. Pérez, C. Bentzen, 2003, Cell Biology and Toxicology.

A new class of calcium entry blockers defined by 1,3-diphosphonates. Interactions of SR-7037 (belfosdil) with receptors for calcium channel ligands.

J. Rossier, J. Cox, E. Niesor, 1989, The Journal of biological chemistry.

Apomine™, an inhibitor of HMG‐CoA‐reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo

P. Croucher, R. Russell, K. Vanderkerken, 2007, International journal of cancer.

Effects of Chenodeoxycholic Acid (CD) Treatment on Endogenous Plasma Triglyceride (TG) Transport in Hyperlipoproteinemia (HLP)

T. M. Hayes, M. Freeman, S. Fujii, 1978 .